US Edition
Prices for new US drugs doubled in 4 years as focus on rare disease grows
- According to a Reuters survey of 45 newly launched medicines, the typical yearly list price in the U.S. More than doubled, rising from $180,000 in 2021 to over $370,000 in 2024.
- This price surge relates mainly to advances in therapies for rare diseases, which now represent 72% of new drug launches and typically command higher prices due to small patient populations.
- The most expensive new drug in 2024 was Lenmeldy, priced at $4.25 million for a one-time gene therapy treating a rare inherited brain and nervous system disorder.
- Patients and insurers often manage high costs through savings programs and rebates, yet experts like Tinglong Dai emphasize the need for streamlined pre-authorization and alternative pricing models similar to Europe's.
- The rising prices suggest continued industry focus and investment in rare disease therapies, with no clear sign of slowing absent significant reductions in development costs.
Insights by Ground AI
Does this summary seem wrong?
8 Articles
8 Articles
All
Left
1
Center
5
Right
1
Prices for new US drugs doubled in 4 years as focus on rare disease grows
U.S. prices for newly-launched pharmaceuticals more than doubled last year compared to 2021, as companies leveraged scientific advances to develop more therapies for rare diseases, which typically command high prices, a Reuters analysis found.
·United Kingdom
Read Full Article
Coverage Details
Total News Sources8
Leaning Left1Leaning Right1Center5Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
14%
C 71%
14%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
